You are here

New High Purity Immunoglobulin Enters Phase III in Europe and the US

Octapharma AG today announced the start of the first of a series of Phase III studies for its new 10% high purity intravenous immunoglobulin (IVIG). The study will investigate the efficacy and safety of this novel immunoglobulin in the treatment of primary immune deficiency and, together with results from additional upcoming studies, will support its regulatory filing inEurope and the US.

New High Purity Immunoglobulin Enters Phase III in Europe and the US

News Category: